NEKTAR THERAPEUTICS (NKTR)
D
Pipeline Grade
Financial Position (from SEC Filings)
$149.6M
Cash & Equivalents
$44.3M
Quarterly Burn Rate
10 mo
Est. Cash Runway
$2,377M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
No upcoming catalysts detected for this company.
Active Clinical Trials (6)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT07690371 | A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatit... | PHASE3 | Recruiting | 510 |
| NCT05327530 | A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urot... | PHASE2 | Active Not Recruiting | 256 |
| NCT05632809 | REStoring lymphoCytes Using NKTR-255* After chemoradiothErapy in Solid Tumors (RESCUE) | PHASE2 | Recruiting | 39 |
| NCT06340360 | A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adu... | PHASE2 | Active Not Recruiting | 94 |
| NCT06136741 | A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopi... | PHASE2 | Active Not Recruiting | 396 |
| NCT05359211 | NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma | PHASE1 | Active Not Recruiting | 27 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.